Timothy Larson

6.9k total citations
30 papers, 792 citations indexed

About

Timothy Larson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Timothy Larson has authored 30 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Timothy Larson's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Timothy Larson is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Timothy Larson collaborates with scholars based in United States, Spain and Japan. Timothy Larson's co-authors include Lyudmila Bazhenova, Paulina Selaru, Vincent A. Miller, Joan H. Schiller, Alejandro D. Ricart, Everett E. Vokes, Shirish M. Gadgeel, Keith D. Wilner, Katherine Liau and Philip J. Stella and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Timothy Larson

29 papers receiving 777 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Larson United States	14	447	373	271	171	100	30	792
Benjamin Suttle United States	9	252 0.6×	513 1.4×	179 0.7×	174 1.0×	126 1.3×	21	750
Deborah Ricci United States	15	474 1.1×	261 0.7×	399 1.5×	115 0.7×	262 2.6×	51	876
Sumie Koike Japan	13	669 1.5×	520 1.4×	506 1.9×	83 0.5×	199 2.0×	19	1.0k
W. Li China	11	684 1.5×	372 1.0×	337 1.2×	159 0.9×	191 1.9×	47	981
Haby Henary United States	14	378 0.8×	376 1.0×	199 0.7×	68 0.4×	117 1.2×	32	702
Vijay Peddareddigari United States	11	600 1.3×	714 1.9×	183 0.7×	127 0.7×	170 1.7×	18	1.2k
Gregory Friberg United States	18	722 1.6×	504 1.4×	318 1.2×	156 0.9×	269 2.7×	35	1.2k
Tobias Arkenau United Kingdom	8	601 1.3×	540 1.4×	263 1.0×	196 1.1×	101 1.0×	22	948
Sujatha Nallapareddy United States	10	440 1.0×	509 1.4×	141 0.5×	103 0.6×	122 1.2×	16	790
Lisa Malburg United States	9	405 0.9×	493 1.3×	181 0.7×	98 0.6×	99 1.0×	14	780

Countries citing papers authored by Timothy Larson

Since Specialization

Citations

This map shows the geographic impact of Timothy Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Larson more than expected).

Fields of papers citing papers by Timothy Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Larson. The network helps show where Timothy Larson may publish in the future.

Co-authorship network of co-authors of Timothy Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Larson. A scholar is included among the top collaborators of Timothy Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Larson. Timothy Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.. Journal of Clinical Oncology. 42(16_suppl). 8047–8047. 1 indexed citations

Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2024). A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 201. 113950–113950. 2 indexed citations

Lenz, Heinz‐Josef, Aparna R. Parikh, David R. Spigel, et al.. (2024). Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. Journal for ImmunoTherapy of Cancer. 12(3). e008409–e008409. 33 indexed citations

Schüler, Martin, Donald A. Berry, H.A. Burris, et al.. (2024). Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial. FreiDok plus (Universitätsbibliothek Freiburg). 1 indexed citations

Friedberg, Jonathan W., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 143(9). 786–795. 14 indexed citations

Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 142(Supplement 1). 4435–4435. 1 indexed citations

Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.. Journal of Clinical Oncology. 41(16_suppl). 9109–9109. 3 indexed citations

Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2023). 1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3. Annals of Oncology. 34. S900–S900. 2 indexed citations

Cutsem, Eric Van, Adriana Valderrama, Yung‐Jue Bang, et al.. (2021). Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. ESMO Open. 6(4). 100189–100189. 13 indexed citations

10.

Fakih, Marwan, Kanwal Raghav, David Chang, et al.. (2021). Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 39(15_suppl). 3560–3560. 52 indexed citations

11.

Picozzi, Vincent J., Adnan Alseidi, Michael J. Pishvaian, et al.. (2020). Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 5(4). e000668–e000668. 54 indexed citations

12.

Taylor, Matthew H., Ajjai Alva, Timothy Larson, et al.. (2020). A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. Oncotarget. 11(14). 1235–1243. 5 indexed citations

13.

Carrier, Ewa, Vincent J. Picozzi, Michael J. Pishvaian, et al.. (2017). Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients. Annals of Oncology. 28. v268–v268. 3 indexed citations

14.

Dudek, Arkadiusz Z., et al.. (2012). Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC. American Journal of Clinical Oncology. 37(2). 140–143. 4 indexed citations

15.

Haura, Eric B., Alejandro D. Ricart, Timothy Larson, et al.. (2010). A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 16(8). 2450–2457. 188 indexed citations

16.

Dudek, Arkadiusz Z., Krzysztof Leśniewski-Kmak, Timothy Larson, et al.. (2009). Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(8). 969–975. 6 indexed citations

17.

Dudek, Arkadiusz Z., Timothy Larson, Michael McCleod, et al.. (2008). Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 394–399. 16 indexed citations

18.

Schiller, Joan H., Joachim von Pawel, Timothy Larson, et al.. (2007). Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial. Clinical Lung Cancer. 8(7). 452–452. 1 indexed citations

19.

Dudek, Arkadiusz Z., et al.. (2007). Dose Escalating Study of Biweekly Gemcitabine and Carboplatin in Patients With Advanced Cancer. American Journal of Clinical Oncology. 30(5). 481–486. 2 indexed citations

20.

Abraham, Roshini S., Raynell Clark, Sandra C. Bryant, et al.. (2002). Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. Clinical Chemistry. 48(4). 655–657. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact